DOYLE MITTIE (Chief Medical Officer) sold 1.3% of their position (679.00 shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $13.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/12/2026ACC: 0001918845-26-000026
Officer· Chief Medical Officer
Since Feb 2026
-679.00
Net shares
Net seller
$13.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
679.00 acquired · 1.36K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+679.00
Price / share
$8.04
Trade value
$5.46K
% of position
1.3%
8/10/2026
51.78K→52.45K
Common Stock
Direct
Shares
−679.00
Price / share
$20.00
Trade value
$13.58K
% of position
1.3%
8/10/2026
52.45K→51.78K
Total
Net shares
+0.00
Net value
-$8.12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/10/2026 | M · Option Exercise | +679.00 | $8.04 | $5.46K | 1.3% | 51.78K | 52.45K |
| Common Stock Direct | 8/10/2026 | S · Sale | −679.00 | $20.00 | $13.58K | 1.3% | 52.45K | 51.78K |
| Total | +0.00 | -$8.12K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
679.00 shares
Shares
−679.00
Strike price
8.04
Held after
114.41K
Exercisable
—
8/10/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock679.00 shares | 8/10/2026 | M · Option Exercise | −679.00 | 8.04 | — | 114.41K |